+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli



Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli



Archives of Internal Medicine 168(17): 1897-1902



Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli is an increasingly important group of community pathogens worldwide. These organisms are frequently resistant to many of the antimicrobial agents usually recommended for the treatment of infections caused by E coli, such as penicillins, cephalosporins, fluoroquinolones, and trimethoprim-sulfamethoxazole. Data concerning risk factors, clinical features, and therapeutic options for such infections are scarce. A case-control study was performed to investigate the risk factors for all types of community-acquired infections caused by ESBL-producing E coli in 11 Spanish hospitals from February 2002 to May 2003. Controls were randomly chosen from among outpatients with a clinical sample not yielding ESBL-producing E coli. The clinical features of these infections were investigated in the case patients. The efficacy of fosfomycin tromethamine and amoxicillin-clavulanate potassium was observationally studied in patients with cystitis. A total of 122 cases were included. Risk factors selected by multivariate analysis included the following: age older than 60 years; female sex; diabetes mellitus; recurrent urinary tract infections (UTIs); previous invasive procedures of the urinary tract; follow-up in outpatient clinic; and previous receipt of aminopenicillins, cephalosporins, and fluoroquinolones. Urinary tract infections accounted for 93% of the cases; 6% of the patients were bacteremic and 10% needed hospitalization. The cure rate of patients with cystitis was 93% with fosfomycin therapy (all isolates were susceptible); among patients treated with amoxicillin-clavulanate, cure rates were 93% for those with susceptible isolates (minimum inhibitory concentration < or =8 microg/mL) and 56% for those with intermediate or resistant isolates (minimum inhibitory concentration > or =16 microg/mL) (P = .02). In predisposed patients, ESBL-producing E coli is a notable cause of community-acquired infection, and particularly UTI. Fosfomycin and amoxicillin-clavulanate appear to be effective for cystitis caused by susceptible isolates.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052203871

Download citation: RISBibTeXText

PMID: 18809817

DOI: 10.1001/archinte.168.17.1897


Related references

Risk factors for community-acquired infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Archives of Internal Medicine 169(8): 811; Author Reply 811-2, 2009

Epidemiology and Risk Factors of Community Onset Infections Caused by Extended-Spectrum beta-Lactamase-Producing Escherichia coli Strains. 2012

Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. European Journal of Clinical Microbiology and Infectious Diseases 27(1): 85-88, 2007

Clinical Prediction Score for Community-Onset Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella Species. Journal of Korean Medical Science 34(14): E116, 2019

Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities. International Journal of Clinical Practice 69(7): 766-770, 2016

Mecillinam/clavulanate combination a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. 2012

Analysis of community-associated bloodstream infections caused by Escherichia coli producing extended-spectrum β-lactamase. Zhonghua Yi Xue Za Zhi 95(26): 2084-2089, 2016

Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68(6): 1169-1174, 2006

Characteristics of infections caused by extended-spectrum β-lactamase-producing Escherichia coli from community hospitals in South Africa. Diagnostic Microbiology and Infectious Disease 69(4): 449-453, 2011

Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clinical Microbiology and Infection 14(2): 180-183, 2007

Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagnostic Microbiology and Infectious Disease 56(3): 313-315, 2006

Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Singapore Medical Journal 48(6): 600-601, 2007

Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. Journal of Clinical Microbiology 50(2): 312-317, 2012

Efficacy of various antimicrobial agents in infections caused by extended spectrum beta-lactamase producing Escherichia coli and Klebsiella species. Abstracts of the General Meeting of the American Society for Microbiology 103: A-058, 2003

Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. Journal of Clinical Microbiology 42(3): 1089-1094, 2004